Cite
HARVARD Citation
Zakharia, Y. et al. (n.d.). 514 Results of Phase 1b trial of the Indoleamine 2, 3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma. European journal of cancer. pp. S108-. [Online].